Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral drug for postpartum depression aces phase 3 trial

Key clinical point: An investigational, once-daily oral drug known as SAGE-217 provides a major advance in treatment of postpartum depression.

Major finding: At day 15, the women who received oral SAGE-217 had a mean 17.8-point improvement in HAM-D scores, significantly better than the 13.6-point reduction with placebo.

Study details: The phase 3 multicenter ROBIN study included 151 patients with postpartum depression who were randomized double-blind to 14 days of SAGE-217 at 30 mg once daily or placebo.

Disclosures: The presenter reported serving on advisory boards for Sage Therapeutics, the study sponsor, as well as for two dozen other pharmaceutical companies.


Vieta E. ECNP Congress, Session S08.08